# Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

> **NCT06055777** · PHASE1 · TERMINATED · sponsor: **Suzhou Erye Pharmaceutical Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Infections

## Interventions

- **DRUG:** SZEY-2108 for injetion
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06055777
- **Lead sponsor:** Suzhou Erye Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-07
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** Due to the termination criteria for dose escalation in the clinical protocol having been reached, this trial is terminated.
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055777, "Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06055777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*